Sp138
IBD YEAR IN REVIEW
Date
May 18, 2024
Explore related products in the following collection:
Presenters
University of California san francisco
University of North Carolina School of Medicine
Tracks
Related Products
PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
BACKGROUND: Pregnant women with ulcerative colitis (UC) have a higher risk of adverse pregnancy outcomes vs age-matched controls.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of UC. There are no well-controlled studies on tofacitinib use in pregnant women…
COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN’S DISEASE.
INTRODUCTION: Recent guidelines propose a fecal calprotectin (FCP) monitoring strategy in the year after Crohn’s disease (CD) resection for low-risk individuals or those receiving pharmacologic prophylaxis to prevent postoperative recurrence (POR)…
Farron and Martin Brotman, MD, Lecture - Key Challenges in IBD: Strategies and Solutions from the Experts
SOCIETY: AGA Management of IBD is complex and challenging…
ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY
Background: We compared real-world outcomes of upadacitinib (upa) vs tofacitinib (tofa) for ulcerative colitis (UC) through 52 weeks…
